[Market Highlight] PharmaResearch Rises on Forecast of 93% Surge in Q4 Operating Profit

PharmaResearch is showing strong performance. This is believed to be influenced by securities industry analysis suggesting that operating profit in the fourth quarter of last year will increase by approximately 93%.

As of 10:25 a.m. on January 23, PharmaResearch was trading at 472,000 won, up 3.51% from the previous day.

On this day, Cho Eunae, a researcher at LS Securities, stated, "PharmaResearch's estimated sales for the fourth quarter of last year are 155.9 billion won, representing a 51% increase year-on-year and a 15% increase quarter-on-quarter." She added, "During the same period, operating profit is expected to reach 65 billion won, up 93% year-on-year and 5% quarter-on-quarter."

Domestic medical device sales are estimated to reach 65.8 billion won, representing a 57% increase year-on-year and a 15% increase quarter-on-quarter. In particular, the amount spent by foreign dermatology consumers reached 383 billion won, up 75% year-on-year and 28% quarter-on-quarter, which is cited as a key factor raising expectations for performance.

Export medical device sales are projected to reach 24.5 billion won, up 25% year-on-year and 25% quarter-on-quarter. Considering that the export amount from Gangneung City in the fourth quarter of last year, announced on January 15, was $23.28 million-an increase of 106% year-on-year and 15% quarter-on-quarter-the sales target appears to be well within reach.

Researcher Cho analyzed, "The growth trend is expected to continue this year as well," adding, "With the continued benefit from expanding inbound consumption and the full-scale expansion of exports to Europe and the United States, there is a high possibility that both sales and profits will continue their strong growth."